Currently Closed – We are no longer accepting or processing applications for new or renewal patients.
The PAN Foundation’s Non-Small Cell Lung Cancer fund is currently closed. As of December 11, 2017, Healthwell is accepting re-enrollment applications.
$4,800 per year. Patients may apply for a second grant during their eligibility period subject to availability of funding.
- The patient must be getting treatment for the disease named in the assistance program to which he or she is applying.
- The patient must have Medicare health insurance that covers his or her qualifying medication or product.
- The patient’s medication or product must be listed on PAN’s list of covered medications.
- The patient’s income must fall at or below 500% the Federal Poverty Level.
- The patient must reside and receive treatment in the United States or U.S. territories. (U.S. citizenship is not a requirement.)
See the list of medications covered in this program
- Abraxane (paclitaxel protein-bound)
- Afinitor (everolimus)
- Alecensa (alectinib hcl)
- Alimta (pemetrexed disodium)
- Alunbrig (brigatinib)
- Avastin (bevacizumab)
- Cabometyx (cabozantinib s-malate)
- Camptosar (irinotecan hcl)
- Carboplatin (carboplatin)
- Cisplatin (cisplatin)
- Cometriq (cabozantinib s-malate)
- Cyclophosphamide (cyclophosphamide)
- Cyramza (ramucirumab)
- Docefrez (docetaxel)
- Docetaxel (docetaxel)
- Eloxatin (oxaliplatin)
- Erbitux (cetuximab)
- Etopophos (etoposide phosphate)
- Etoposide (etoposide)
- Gemcitabine Hcl (gemcitabine hcl)
- Gemzar (gemcitabine hcl)
- Gilotrif (afatinib dimaleate)
- Herceptin (trastuzumab)
- Iressa (gefitinib)
- Irinotecan Hcl (irinotecan hcl)
- Keytruda (pembrolizumab)
- Mekinist (trametinib dimethyl sulfoxide)
- Methotrexate Sodium (methotrexate sodium/pf)
- Navelbine (vinorelbine tartrate)
- Opdivo (nivolumab)
- Oxaliplatin (oxaliplatin)
- Paclitaxel (paclitaxel)
- Photofrin (porfimer sodium)
- Portrazza (necitumumab)
- Rheumatrex (methotrexate sodium)
- Tafinlar (dabrafenib mesylate)
- Tagrisso (osimertinib mesylate)
- Tarceva (erlotinib hcl)
- Taxotere (docetaxel)
- Tecentriq (atezolizumab)
- Toposar (etoposide)
- Trexall (methotrexate sodium)
- Vinblastine Sulfate (vinblastine sulfate)
- Vinorelbine Tartrate (vinorelbine tartrate)
- Xalkori (crizotinib)
- Zelboraf (vemurafenib)
- Zortress (everolimus)
- Zykadia (ceritinib)